NNVC (Nanoviricides) Change In Payables And Accrued Expense : $0.73 Mil (TTM As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Change In Payables And Accrued Expense?

Nanoviricides's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.27 Mil. It means Nanoviricides's Accounts Payable & Accrued Expense increased by $0.27 Mil from Jun. 2024 to Sep. 2024 .

Nanoviricides's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2024 was $0.87 Mil. It means Nanoviricides's Accounts Payable & Accrued Expense increased by $0.87 Mil from Jun. 2023 to Jun. 2024 .

Nanoviricides Change In Payables And Accrued Expense Historical Data

The historical data trend for Nanoviricides's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Change In Payables And Accrued Expense Chart

Nanoviricides Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.11

-0.76

0.06

0.22

0.87

Nanoviricides Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.41	0.05	-0.14	0.55	0.27

Nanoviricides Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73 Mil.

Nanoviricides Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoviricides Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NV3P:Germany NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Executives

Makarand Jawadakar	director	C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day	director	C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk	director	C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan	director, 10 percent owner, officer: President	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni	director	C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas	officer: Chief Financial Officer	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour	director, 10 percent owner	666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc.	10 percent owner	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516